Challenges to Early Discharge of Patients with Upper Urinary Tract Infections by ESBL Producers: TMP/SMX as a Step-Down Therapy for Shorter Hospitalization and Lower Costs

References

• BehzadiP, UrbánE, MatuzM, BenkőR, GajdácsM. The role of gram-negative bacteria in urinary tract infections: current concepts and therapeutic options. Adv Exp Med Biol. 2021;1323:35–69. doi:10.1007/5584_2020_56632596751
   PubMed Web of Science ®Google Scholar
• GajdácsM. The importance of reporting clinical and epidemiological data in urology: local experiences and insights from the international literature. Medicina. 2020;56. doi:10.3390/medicina56110581
   Web of Science ®Google Scholar
• SchappertSM, RechtsteinerEA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat 13. 2011;2(169):1–38.
   Google Scholar
• TandogduZ, WagenlehnerFME. Global epidemiology of urinary tract infections. Curr Opin Infect Dis. 2016;29(1):73–79. doi:10.1097/qco.000000000000022826694621
   PubMed Web of Science ®Google Scholar
• ZowawiHM, HarrisPN, RobertsMJ, et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol. 2015;12(10):570–584. doi:10.1038/nrurol.2015.19926334085
   PubMed Web of Science ®Google Scholar
• BenkőR, GajdácsM, MatuzM, et al. Prevalence and antibiotic resistance of ESKAPE pathogens isolated in the emergency department of a tertiary care teaching hospital in hungary: a 5-year retrospective survey. Antibiotics. 2020;9. doi:10.3390/antibiotics9090624
   Web of Science ®Google Scholar
• GajdácsM, ÁbrókM, LázárA, BuriánK. Comparative epidemiology and resistance trends of common urinary pathogens in a tertiary-care hospital: a 10-year surveillance study. Medicina. 2019;55. doi:10.3390/medicina55070356
   Web of Science ®Google Scholar
• TalanDA, TakharSS, KrishnadasanA, et al. Emergence of extended-spectrum β-lactamase urinary tract infections among hospitalized emergency department patients in the United States. Ann Emerg Med. 2021;77(1):32–43. doi:10.1016/j.annemergmed.2020.08.02233131912
   PubMed Web of Science ®Google Scholar
• SeoM-R, KimS-J, KimY, et al. Susceptibility of escherichia coli from community-acquired urinary tract infection to fosfomycin, nitrofurantoin, and temocillin in Korea. J Korean Med Sci. 2014;29(8):1178–1181. doi:10.3346/jkms.2014.29.8.117825120333
   PubMed Web of Science ®Google Scholar
• SuhW, KimBN, KangHM, YangEA, RhimJW, LeeKY. Febrile urinary tract infection in children: changes in epidemiology, etiology, and antibiotic resistance patterns over a decade. Clin Exp Pediatrics. 2020;1:42. doi:10.3345/cep.2020.00773
   Google Scholar
• GajdacsM. Intravenous or oral antibiotic therapy: sophie’s choice? Review article. General Int Med Clin Innovations. 2019;5(3):254. doi:10.15761/GIMCI.1000176
   Google Scholar
• GajdácsM, UrbánE. Epidemiological Trends and resistance associated with stenotrophomonas maltophilia bacteremia: a 10-year retrospective cohort study in a tertiary-care hospital in hungary. Diseases. 2019;7(2):4788. doi:10.3390/diseases7020041
   Web of Science ®Google Scholar
• AslanAT, AkovaM. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options. Expert Rev Anti Infect Ther. 2019;17(12):969–981. doi:10.1080/14787210.2019.169325831722185
   PubMed Web of Science ®Google Scholar
• LobSH, HackelMA, HobanDJ, YoungK, MotylMR, SahmDF. Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012–2016. Eur j Clin Microbiol Infect Dis. 2018;37(8):1481–1489. doi:10.1007/s10096-018-3274-y29754209
   PubMed Web of Science ®Google Scholar
• KangCI, KimJ, ParkDW, et al. Clinical practice guidelines for the antibiotic treatment of community-acquired urinary tract infections. Infect Chemotherapy. 2018;50(1):67–100. doi:10.3947/ic.2018.50.1.67
   PubMed Web of Science ®Google Scholar
• GajdácsM, ÁbrókM, LázárA, BuriánK. Revival of older antibiotics for the therapy of urinary tract infections: old, but gold Part 1: antimicrobial susceptibility of extended-spectrum β-lactamase-producing and AmpC β-lactamase-producing Escherichia coli isolates. Rev Med Microbiol. 2021;32(1):51–56. doi:10.1097/mrm.0000000000000220
   Web of Science ®Google Scholar
• Institute CaLS. Performance Standards for Antimicrobial Susceptibility Testing. 30th edition. Guidelines; 2020: 296.
   Google Scholar
• GuptaK, HootonTM, NaberKG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious diseases society of america and the european society for microbiology and infectious diseases. Clin Infecti Dis. 2011;52(5):e103–20. doi:10.1093/cid/ciq257
   PubMed Web of Science ®Google Scholar
• HootonTM, BradleySF, CardenasDD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International clinical practice guidelines from the infectious diseases society of America. Clin Infecti Dis. 2010;50(5):625–663. doi:10.1086/650482
   PubMed Web of Science ®Google Scholar
• MendesRE, CastanheiraM, WoosleyLN, StoneGG, BradfordPA, FlammRK. Molecular beta-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam Phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: efficacies analysed against susceptible and resistant subsets. Int J Antimicrob Agents. 2018;52(2):287–292. doi:10.1016/j.ijantimicag.2018.04.00129654893
   PubMed Web of Science ®Google Scholar
• BartolettiR, CaiT, WagenlehnerFM, NaberK, Bjerklund JohansenTE. Treatment of urinary tract infections and antibiotic stewardship. Eur Urol Supplements. 2016;15(4):81–87. doi:10.1016/j.eursup.2016.04.003
   Web of Science ®Google Scholar
• AuerS, WojnaA, HellM. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2010;54(9):4006–4008. doi:10.1128/aac.01760-0920585127
   PubMed Web of Science ®Google Scholar
• KotB. Antibiotic resistance among uropathogenic escherichia coli. Polish j Microbiol. 2019;68(4):403–415. doi:10.33073/pjm-2019-048
   Web of Science ®Google Scholar
• DubourgG, OkdahL, Le PageS, RolainJ-M, RaoultD. In vitro activity of ‘old antibiotics’ against highly resistant Gram-negative bacteria. Int J Antimicrob Agents. 2015;46(6):718–720. doi:10.1016/j.ijantimicag.2015.09.00826589488
   PubMed Web of Science ®Google Scholar
• GajdácsM, BátoriZ, ÁbrókM, LázárA, BuriánK. Characterization of resistance in gram-negative urinary isolates using existing and novel indicators of clinical relevance: a 10-year data analysis. Life. 2020;10:10. doi:10.3390/life10020016
   Google Scholar
• CockerillFR, EdsonRS. Trimethoprim-sulfamethoxazole. Mayo Clinic Proce. 1991;66(12):1260–1269. doi:10.1016/s0025-6196(12)62478-1
   PubMed Web of Science ®Google Scholar
• McMeekinN, GeueC, BriggsA, et al. Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. Wellcome Open Res. 2019;4:108. doi:10.12688/wellcomeopenres.15314.431930174
   PubMedGoogle Scholar
• RubinN, FoxmanB. The cost-effectiveness of placing urinary tract infection treatment over the counter. J Clin Epidemiol. 1996;49(11):1315–1321. doi:10.1016/s0895-4356(96)00218-18892501
   PubMed Web of Science ®Google Scholar
• ZhangY, WangQ, YinY, et al. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: report from the China CRE Network. Antimicrob Agents Chemother. 2018;62(2). doi:10.1128/aac.01882-17
   Web of Science ®Google Scholar
• CritchleyIA, CotroneoN, PucciMJ, MendesR. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017. PLoS One. 2019;14(12):e0220265. doi:10.1371/journal.pone.022026531821338
   PubMed Web of Science ®Google Scholar
• ZimmermannP, CurtisN. The effect of antibiotics on the composition of the intestinal microbiota - a systematic review. J Infect. 2019;79(6):471–489. doi:10.1016/j.jinf.2019.10.00831629863
   PubMed Web of Science ®Google Scholar
• GajdácsM, ÁbrókM, LázárA, et al. Detection of VIM, NDM and OXA-48 producing carbapenem resistant Enterobacterales among clinical isolates in Southern Hungary. Acta Microbiol Immunol Hung. 2020;67(4):209–215. doi:10.1556/030.2020.01181
   Web of Science ®Google Scholar
• VeveMP, WagnerJL, KenneyRM, GrunwaldJL, DavisSL. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. Int J Antimicrob Agents. 2016;48(1):56–60. doi:10.1016/j.ijantimicag.2016.04.01427234673
   PubMed Web of Science ®Google Scholar
• BielenL, LikicR. Experience with fosfomycin in the treatment of complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Therapeutic Adv Infect Dis. 2019;6:2049936119858883. doi:10.1177/2049936119858883
   Web of Science ®Google Scholar
• ChinTW, VandenbrouckeA, FongIW. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob Agents Chemother. 1995;39(1):28–33. doi:10.1128/aac.39.1.287695325
   PubMed Web of Science ®Google Scholar
• PaulM, BisharaJ, YahavD, et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ. 2015;350:h2219–h2219. doi:10.1136/bmj.h221925977146
   PubMed Web of Science ®Google Scholar
• Eliakim-RazN, HellermanM, YahavD, et al. Trimethoprim/sulfamethoxazole versus vancomycin in the treatment of healthcare/ventilator-associated MRSA pneumonia: a case-control study. J Antimicrob Chemother. 2017;72(3):882–887. doi:10.1093/jac/dkw51027999052
   PubMed Web of Science ®Google Scholar